Are insulin sensitizers the new strategy to treat Type 1 diabetes? A long-acting dual amylin and calcitonin receptor agonist improves insulin-mediated glycaemic control and controls body weight.

Simone Anna MelanderAnna Thorsø LarsenMorten Asser KarsdalKim Henriksen

Published in: British journal of pharmacology (2024)

The insulin sensitizer KBP-336 lowered glucagon secretion while attenuating insulin-induced weight gain. Additionally, KBP-336 may prevent hypoglycaemia and improve insulin resistance, which could be a significant advantage for individuals with T1D seeking therapeutic benefits.

Keyphrases

type diabetes
glycemic control
insulin resistance
weight gain
body weight
cardiovascular disease
body mass index
birth weight
mental health
weight loss
polycystic ovary syndrome
skeletal muscle
preterm birth
stress induced